GuidelineGut2024
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.
Guideline in Gut, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Progression to Decompensation of Severe Fibrosis Compared to Cirrhosis in MASLD: A Systematic Review and Meta-Analysis.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.Bioactive materials · 2027Review
- A comparison of contrast-to-noise ratio of liver tumors between dynamic contrast-enhanced CT and respiration-tracked 4D-CT for radiotherapy targeting.The British journal of radiology · 2026Article
- Machine Learning Predicts Hepatocellular Carcinoma Risk from Routine Clinical Data: A Large Population-Based Multicentric Study.Cancer discovery · 2026Article
- Article
- Pattern of progression and post-progression survival following transarterial embolisation: An analysis of the TACE-2 and TACTICS trials.JHEP reports : innovation in hepatology · 2026Article
- Physical Activity and Hepatocellular Carcinoma Outcomes: a Narrative Review of Pre-clinical, Observational, and Interventional Evidence.Journal of gastrointestinal cancer · 2026Review
- Central histopathological review of a European hepatocellular carcinoma cohort: impact of the WHO 2019 classification on histological diagnosis and TNM staging.Virchows Archiv : an international journal of pathology · 2026Article
- Perivascular versus nonperivascular hepatocellular carcinoma treated with liver resection: a retrospective propensity score matching comparison of long-term outcomes.Quantitative imaging in medicine and surgery · 2026Article
- Improving surgical treatments for hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2026Review
- Developing an interpretable machine learning model via SHAP to predict HCC postoperative survival based on tumor immune microenvironment CODEX immunomics and MRI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- From algorithms to adaptive frameworks: from square to circle in hepatocellular carcinoma management.Hepatobiliary surgery and nutrition · 2026Article
- Antigen-specific CD8British journal of cancer · 2026Article
- Role of Liver Function in the Multiparametric Assessment of Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2026Review
- Integrated Bioinformatics Analysis Revealing that the NSDHL Gene Might Be Associated with the Progression of Western HFD/SW-Induced Hepatocellular CarcinomaEndocrine, metabolic & immune disorders drug targets · 2026Article
- Hepatocellular Cancer in the Real World-Rising Detection With Same Outcomes.Gastro hep advances · 2026Review
- The UK National Appeals Panel Safely Extends Access to Liver Transplantation for Candidates Beyond Standard Listing Criteria.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Transarterial infusion chemotherapy for severe hepatic dysfunction and poor performance status in diffuse hepatic metastasis: A case report.Oncology letters · 2025Article
- Hepatocellular carcinoma (HCC): An update on risk factors, surveillance, diagnosis and treatment strategies.Clinical medicine (London, England) · 2025Review
- Myeloid cells in chronic liver inflammation.Cellular & molecular immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.